[go: up one dir, main page]

TR201721824A2 - A MODIFIED EMISSION COMBINATION CONTAINING LINAGLIPTIN AND METFORMIN - Google Patents

A MODIFIED EMISSION COMBINATION CONTAINING LINAGLIPTIN AND METFORMIN Download PDF

Info

Publication number
TR201721824A2
TR201721824A2 TR2017/21824A TR201721824A TR201721824A2 TR 201721824 A2 TR201721824 A2 TR 201721824A2 TR 2017/21824 A TR2017/21824 A TR 2017/21824A TR 201721824 A TR201721824 A TR 201721824A TR 201721824 A2 TR201721824 A2 TR 201721824A2
Authority
TR
Turkey
Prior art keywords
metformin
combination containing
linagliptin
emission combination
modified emission
Prior art date
Application number
TR2017/21824A
Other languages
Turkish (tr)
Inventor
Türkyilmaz Ali̇
Pehli̇van Akalin Nur
Ergun Donmez Merve
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority to TR2017/21824A priority Critical patent/TR201721824A2/en
Priority to PCT/TR2018/050870 priority patent/WO2019132833A1/en
Publication of TR201721824A2 publication Critical patent/TR201721824A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Mevcut buluş, linagliptin, metformin ve en az bir modifiye salım sağlayan ajan içeren farmasötik tablet formülasyonu ile ilgilidir. Ayrıca mevcut buluş, söz konusu formülasyonu hazırlama yöntemi de sunmaktadır.The present invention relates to a pharmaceutical tablet formulation comprising linagliptin, metformin and at least one modified release agent. In addition, the present invention provides a method of preparing said formulation.

TR2017/21824A 2017-12-26 2017-12-26 A MODIFIED EMISSION COMBINATION CONTAINING LINAGLIPTIN AND METFORMIN TR201721824A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
TR2017/21824A TR201721824A2 (en) 2017-12-26 2017-12-26 A MODIFIED EMISSION COMBINATION CONTAINING LINAGLIPTIN AND METFORMIN
PCT/TR2018/050870 WO2019132833A1 (en) 2017-12-26 2018-12-24 The modified release combination comprising linagliptin and metformin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2017/21824A TR201721824A2 (en) 2017-12-26 2017-12-26 A MODIFIED EMISSION COMBINATION CONTAINING LINAGLIPTIN AND METFORMIN

Publications (1)

Publication Number Publication Date
TR201721824A2 true TR201721824A2 (en) 2019-07-22

Family

ID=65444312

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2017/21824A TR201721824A2 (en) 2017-12-26 2017-12-26 A MODIFIED EMISSION COMBINATION CONTAINING LINAGLIPTIN AND METFORMIN

Country Status (2)

Country Link
TR (1) TR201721824A2 (en)
WO (1) WO2019132833A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023163510A1 (en) * 2022-02-23 2023-08-31 주식회사 제뉴원사이언스 Pharmaceutical complex formulation with controlled drug release comprising linagliptin or pharmaceutically acceptable salt thereof and metformin or pharmaceutically acceptable salt thereof
EP4548913A1 (en) * 2023-11-06 2025-05-07 Genepharm S.A. A monolayer tablet of linagliptin and metformin
WO2025157944A1 (en) * 2024-01-23 2025-07-31 Genepharm S.A. A tablet of linagliptin and metformin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011295837B2 (en) * 2010-09-03 2015-06-18 Astrazeneca Uk Limited Drug formulations using water soluble antioxidants
UY33937A (en) * 2011-03-07 2012-09-28 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITIONS CONTAINING DPP-4 AND / OR SGLT-2 AND METFORMIN INHIBITORS
IN2013MU03847A (en) * 2013-12-09 2015-07-24 Intas Pharmaceuticals Ltd
US20160106677A1 (en) * 2014-10-17 2016-04-21 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
KR101526825B1 (en) * 2014-12-23 2015-06-08 주식회사 한독 Pharmaceutical Compositions for The Treatment of Diabetes
US20180344647A1 (en) 2015-12-04 2018-12-06 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof

Also Published As

Publication number Publication date
WO2019132833A1 (en) 2019-07-04

Similar Documents

Publication Publication Date Title
EP3891149A4 (en) RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
SV2017005461A (en) BENZAMIDS REPLACED WITH 1,3-TIAZOL-2-ILO
MX2016014320A (en) Extended release suspension compositions.
MX2021014242A (en) USE OF LINAGLIPTIN IN CARDIO- AND RENOPROTECTIVE ANTI-DIABETIC THERAPY.
TR201818825T4 (en) LNCRNAS FOR THE TREATMENT AND DIAGNOSIS OF CARDIAC HYPERTROPHY
DOP2016000253A (en) NEW COMPOUNDS
MX389178B (en) FIXED RATIO FORMULATION OF INSULIN GLARGINE/LIXISENATIDE.
EA201692043A1 (en) DOSAGE FORM IMMUNODEPRESSANT
MX2017006953A (en) Medicaments for slowing parkinson's disease.
CR20150266A (en) MODIFIED RELEASE FORMULATIONS FOR OPROZOMIB
CY1122473T1 (en) HIGH DOSE OPTIMIZED MID-SALIZED TABLET
AR093939A1 (en) COMPOSITIONS THAT INCLUDE VORTIOXETINA AND DONEPEZIL
TR201721824A2 (en) A MODIFIED EMISSION COMBINATION CONTAINING LINAGLIPTIN AND METFORMIN
TR201720406A2 (en) COMBINATIONS CONTAINING A SKELETAL MUSCLE LOAER AND A MULTIPLE SCLEROSIS THERAPY
EA202090913A1 (en) COMPOSITION OF MODIFIED RELEASE TABLETS CONTAINING MIRABEGRON
CY1123219T1 (en) ENHANCED ALPHA V BETA 8 ANTIBODIES
CL2019003288A1 (en) A pharmaceutical combination for the treatment of cancer.
ECSP16005208A (en) STABLE ANTI-TUBERCULOSIS PHARMACEUTICAL COMPOSITION IN A FORM OF A COATED TABLET INCLUDING ISONIAZID GRANULES AND RIFAPENTINE GRANULES AND THEIR PREPARATION PROCESS
TR201720515A2 (en) A SOLID ORAL DOSAGE FORM CONTAINING LINAGLIPTIN
CY1122708T1 (en) OXA-DIAZASPIRE COMPOUNDS WITH ACTION AGAINST PAIN
MX2018002075A (en) COMPOSITION THAT INCLUDES TANINS.
MX2017013634A (en) FIXED DOSE COMBINATION RESISTANT TO HANDLING THAT PROVIDES A QUICK RELEASE OF TWO DRUGS FROM PARTICLES AND A POWDER.
MX2017013633A (en) FIXED DOSE COMBINATION RESISTANT TO HANDLING THAT PROVIDES A QUICK RELEASE OF TWO PHARMACES FROM PARTICLES.
TR201815617A2 (en) A formulation containing dexketoprofen.
CY1120192T1 (en) UNIONS TO ENHANCE KNOWLEDGE FUNCTIONING